Pliant Therapeutics Appoints Two Directors; Board Expanded to Nine

What Happened

• Pliant Therapeutics, Inc. (PLRX) announced on July 13, 2026 (effective July 9, 2026) that its Board increased from seven to nine members and appointed Robert Iannone, M.D., M.S.C.E., as a Class I director and Flavia Borellini, Ph.D., as a Class II director.
• The Board named Dr. Iannone a member of the Research & Development (R&D) Committee and appointed Dr. Borellini as chair of the R&D Committee. The Board determined both appointees are independent and meet SEC and Nasdaq requirements.

Key Details

• Effective date: July 9, 2026; filing date: July 13, 2026.
• Cash retainers: each new non-employee director will receive an annual retainer of $40,000 (pro-rated for partial service); R&D committee retainers are $7,500 (member) for Dr. Iannone and $15,000 (chair) for Dr. Borellini (pro-rated).
• Equity awards: each new director received an option to purchase 60,000 shares of common stock, vesting in substantially equal monthly installments over three years, subject to continuous board service (total potential options granted = 120,000 shares).
• The company entered into its standard form of indemnification agreement with both directors; no related-party transactions were reported.

Why It Matters

• Governance: Adding two independent directors and filling R&D Committee roles strengthens board oversight of research and development activities, a core area for a clinical-stage biotech like Pliant.
• Compensation and dilution: The appointments include cash retainers and option grants; if exercised, the two 60,000-share options could result in up to 120,000 additional shares outstanding, which is a concrete—but typically modest—source of dilution to monitor.
• Investor takeaway: This 8-K is primarily a governance update (director additions, committee leadership, and standard director compensation). Investors should note the new R&D chair and member given their potential influence on development strategy and oversight, while recognizing these are routine director hires disclosed under SEC rules.